Frontlight ResearchEarly access
CompletedPhase 2
The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 25 people enrolled
- Started
- 10 Apr 2024
- Ended
- 16 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Tofacitinib 5 MG BID
- Record updated
- 26 October 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years old
- Patients treated with ICI immunotherapy (monotherapy or combination), including anti-PD1, anti-PDL1, anti-CTLA4; and including any type of cancer (even those in which ICI is not currently approved by regulatory)
- Definite, probable or possible ICI-induced myocarditis according to the diagnostic criteria of the most recent expert consensus recommendations (e.g27, to be updated with any new recommendations to be published)
- corticosteroid-resistant ICI-myocarditis: Corticosteroid-resistant ICI-myocarditis is defined by the absence of decrease in troponin levels or the appearance/persistence of severity criteria despite receiving prednisone dose ≥0.5 mg/kg/day for ≥2 days
- Signature of informed consent before any trial procedure from the patient or legal representative or the close relative
- Patients covered by social security regimen (excepting AME)
- Withhold of ICI
Who cannot take part
- Being treated with tofacitinib within 3 months prior to inclusion Known hypersensitivity to abatacept or belatacept
- Being treated with anti-thymoglobulin, or alemtuzumab within 6 weeks of the first scheduled dose of abatacept
- Untreated and/or uncontrolled bacterial, fungal, or viral infection Pregnancy, breast-feeding or planning to become pregnant during the study period
- For women of childbearing age, lack of effective contraception throughout the duration of participation in the study
- Patient participating to another interventional study (RIPH 1 only) People under legal protection measure (tutorship, curatorship or safeguard measures)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The efficacy and safety of Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a single-arm, prospective, phase 2 trial
The group in the trial
- TofacitinibTreatment being tested
Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis
Treatment: Tofacitinib 5 MG BID
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis: a Single-arm, Prospective, Phase 2 Trial
- Record updated
- 26 October 2026